Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine

Xenobiotica

Volumn 41, Issue 1, 2011, Pages 46-58

  Ye, Ling ^a   Tang, Lan ^a   Gong, Yun ^a   Lv, Chang ^a   Zheng, Zhijie ^a   Jiang, Zhihong ^a,b   Liu, Zhongqiu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Cytochrome P450; LC MS MS; Mesaconitine; Metabolism; Microsomes

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; MESACONITINE;

ARTICLE; CLINICAL ASSESSMENT; DEHYDROGENATION; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; MASS SPECTROMETRY;

ACONITINE; ADULT; AGED; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MALE; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; MIDDLE AGED; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TIME FACTORS; YOUNG ADULT;

ACONITUM;

EID: 78650186681     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.524950     Document Type: Article

References (26)

1. Ameri A. (1998). The effects of Aconitum alkaloids on the central nervous system. Prog Neurobiol 56:211-235.
2. Ando Y, Fuse E, Figg WD. (2002). Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973.
3. Bachmann KA, Ghosh R. (2001). The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2:299-314.
4. Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M. (2004). Potential beneficial metabolic interactions between tamoxifen and isoflaVones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm Res 21:2095-2104.
5. Dresser GK, Spence JD, Bailey DG. (2000). Pharmacokinetic- pharmacodynamic consequences and clinical releVance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
6. Eagling VA, Tjia JF, Back DJ. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
7. FDA. (2006). Guidance for Industry: Drug Metablism/Drug Interaction Studies in the Drug Development Process: Studies In vitro.
8. Hikino H, Murayama M. (1985). Mechanism of the antinociceptive action of mesaconitine: Participation of brain stem and lumbar enlargement. Br J Pharmacol 85:575-580.
9. Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ. (2003). IDentification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflaVones. Drug Metab Dispos 31:924-931.
10. Isono T, Oyama T, Asami A, Suzuki Y, Hayakawa Y, Ikeda Y, Noguchi M, Omiya Y. (1994). The analgesic mechanism of processed Aconiti tuber: The involvement of descending inhibitory system. Am J Chin Med 22:83-94.
11. Kobayashi K, Urashima K, Shimada N, Chiba K. (2003). Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833-836.
12. Li AP, Kaminski DL, Rasmussen A. (1995). Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
13. Liu W, Tang L, Ye L, Cai Z, Xia B, Zhang J, Hu M, Liu Z. (2010). Species and gender differences affect the metabolism of emodin via glucuronidation. AAPS J 12:424-436.
14. Mitamura M, Boussery K, Horie S, Murayama T, Van De Voorde J. (2002a). Vasorelaxing effect of mesaconitine, an alkaloid from Aconitum japonicum, on rat small gastric artery: Possible involvement of endothelium-derived hyperpolarizing factor. Jpn J Pharmacol 89:380-387.
15. 2+ influx and nitric-oxide synthase in the endothelium. Eur J Pharmacol 436:217-225.
16. 2+ exchangers in endothelial cells. Eur J Pharmacol 483:139-146.
17. Ohno Y. (1998). The experimental approach to the murder case of aconite poisoning. J Tox Rev 17:1-11.
18. Omura T. (1999). Forty years of cytochrome P450. Biochem Biophys Res Commun 266:690-698.
19. Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, Zanovello P, Floreani M. (2005). Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 11:1608-1617.
20. Schmider J, Greenblatt DJ, Fogelman SM, Von Moltke LL, Shader RI. (1997). Metabolism of dextromethorphan in vitro: Involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 18:227-240.
21. Suzuki Y, Oyama T, Ishige A, Isono T, Asami A, Ikeda Y, Noguchi M, Omiya Y. (1994). Antinociceptive mechanism of the aconitine alkaloids mesaconitine and benzoylmesaconine. Planta Med 60:391-394.
22. Wacher VJ, Wu CY, Benet LZ. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134.
23. Wang Y, Wang S, Liu Y, Yan L, Dou G, Gao Y. (2006). Characterization of metabolites and cytochrome P450 isoforms involved in the microsomal metabolism of aconitine. J Chromatogr B Analyt Technol Biomed Life Sci 844:292-300.
24. Wilkinson GR. (2005). Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
25. Xie FM, Wang HC, Shu HL, Li JH, Jiang JR, Chang JP, Hsieh YY. (1990). Separation and characterization of the metabolic products of lappaconitine in rat urine by high-performance liquid chromatography. J Chromatogr 526:109-118.
26. Zhang HG, Sun Y, Duan MY, Chen YJ, Zhong DF, Zhang HQ. (2005). Separation and iDentification of Aconitum alkaloids and their metabolites in human urine. Toxicon 46: 500-506.